# Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial

Study · id `cardio:ct-nct06756945` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06756945](<https://clinicaltrials.gov/study/NCT06756945>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06756945

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3612 participants.

## Technical summary

Registry record NCT06756945. Randomized; double masking; primary purpose treatment. Start 2025-01 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3612 participants (planned count; ClinicalTrials.gov record NCT06756945, source copy `cardio:ctgov-nct06756945-2025-01-03`, retrieved 2026-10-26)
- Planned start: 2025-01 (anticipated) (ClinicalTrials.gov record NCT06756945, source copy `cardio:ctgov-nct06756945-2025-01-03`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06756945, source copy `cardio:ctgov-nct06756945-2025-01-03`, retrieved 2026-10-26)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT06756945, source copy `cardio:ctgov-nct06756945-2025-01-03`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06756945-2025-01-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial
- Acronym: LEAST
- Condition: ST-elevation Myocardial Infarction (STEMI)
- Intervention (Drug): aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily
- Intervention (Drug): aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: dd3db925d50d16a70ca5d1d8356fa8e3b0b028af49561ee9b154b6c8a35a4f42
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
